官方APP下载:英语学习播客(支持苹果手机、安卓手机)
创办于2003年
UNSV记不住?那就记中文谐音“忧安思危”吧!
  Slow and Steady Wins the Race!
UNSV英语学习频道 - Slow and steady wins the race!
公众微信服务号
英语全能特训(微信公众服务号)
UNSV英语学习频道淘宝网店
客服短信:18913948480
客服邮箱:web@unsv.com
初级VIP会员
全站英语学习资料下载。
¥98元/12个月

World's Costliest Medicine Is Gene Treatment Priced at $2 Million

作者:Bryan Lynn 发布日期:6-3-2019

U.S. officials have approved the costliest medicine in history – a $2.1-million gene therapy that treats a rare childhood disease.

Gene therapy is a medical treatment in which healthy genetic material is introduced into cells to replace abnormal genes.

The new gene therapy targets a disease called spinal muscular atrophy (SMA), which severely weakens a child's muscles. The treatment, called Zolgensma, was developed by Swiss drugmaker Novartis.

Over time, SMA can make it impossible for the child to move, swallow or breathe. The disease affects about 1 in 10,000 births. In 90 percent of cases, the condition causes death or the need for permanent breathing assistance by age two.

SMA is the leading cause of genetic infant death.

This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA. (Novartis via AP)
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA. (Novartis via AP)

The U.S. Food and Drug Administration (FDA) recently approved Zolgensma for use in children who are under the age of two with SMA. The approval covers babies with the deadliest kind of the disease as well as those with forms that develop more slowly over time.

Novartis says Zolgensma is designed to repair the genetic cause of SMA by replacing a patient's abnormal or missing gene to halt progression of the disease. The one-time treatment can be performed in about an hour.

Novartis has defended the high cost of the gene therapy. It says the treatment represents a new kind of "transformational medicine" that opens the door to future gene therapies. It also said the $2.1-million therapy was about 50 percent less than other SMA treatments that can be ongoing for years.

Novartis said it will let health insurance companies break up the cost in payments of $425,000 over five years. It also plans to give money back if the treatment does not work.

A logo of Swiss pharmaceutical company Novartis is seen at the Novartis Korea office in Seoul, South Korea, Saturday, Aug. 13, 2016. (AP Photo/Ahn Young-joon)
A logo of Swiss pharmaceutical company Novartis is seen at the Novartis Korea office in Seoul, South Korea, Saturday, Aug. 13, 2016. (AP Photo/Ahn Young-joon)

The FDA said the drug's safety had been tested in completed and ongoing trials involving 36 patients between the ages of two weeks and eight months.

Most evidence of the treatment's effectiveness is based on the ongoing trials. In patient testing, babies with the most severe form of SMA who got Zolgensma within 6 months of birth had limited muscle problems.

Those who got the treatment very early in life did the best. Babies who were given Zolgensma after six months stopped losing muscle control, but the medicine was not able to correct damage already done.

The trial found the treatment "demonstrated significant improvement in their ability to reach developmental motor milestones.' These included head control and the ability to sit without support.

The one other medicine for SMA approved in the U.S. is a drug called Spinraza. Instead of a one-time treatment, it must be given every four months. The U.S.-based Biogen, Spinraza's maker, charges $750,000 for the first year of treatment, followed by $350,000 per year after that.

The independent not-for-profit group Institute for Clinical and Economic Review rates the value of costly new medicines. The group said it considers the price of Zolgensma acceptable because it greatly "transforms the lives of families affected by this devastating disease."

In this file photo, Dr. Albert Maguire (R), at the Children's Hospital of Philadelphia, checks the eyes of Misa Kaabali, 8, who was 4-years-old when he received his gene therapy treatment, Oct. 4, 2017.
In this file photo, Dr. Albert Maguire (R), at the Children's Hospital of Philadelphia, checks the eyes of Misa Kaabali, 8, who was 4-years-old when he received his gene therapy treatment, Oct. 4, 2017.

While it is too early to know how long the effectiveness of the treatment will last, some doctors have hope that it could last a lifetime. Dr. Jerry Mendell is a neurologist at Nationwide Children's Hospital in Columbus, Ohio. He led one of the early patient studies involving Zolgensma.

When asked whether he believes the drug will continue to have long-lasting effects, Mendell told the Associated Press, "it's beginning to look that way."

He noted that some of those treated as babies are now 4 or 5 years old with no signs of the disease.

I'm Bryan Lynn.

Bryan Lynn wrote this story for VOA Learning English, based on reports from the Associated Press, Reuters, Agence France-Presse and online sources. Ashley Thompson was the editor.

What are your thoughts on such high-price gene therapies? Write to us in the Comments section, and visit our Facebook page.

Quiz - World's Costliest Medicine Is Gene Treatment Priced at $2 Million

Start the Quiz to find out

Start Quiz

Words in This Story

infant n.a baby or very young child

transformational adj.able to produce a big change or improvement in a situation

significant adj.important, large or great

milestone n.an important event in the development or history of something

devastating adj.causing great damage of suffering

版权所有©2003-2019 南京通享科技有限公司,保留所有权利。未经书面许可,严禁转载本站内容,违者追究法律责任。 互联网经营ICP证:苏B2-20120186
网站备案:苏公网安备 32010202011039号苏ICP备05000269号-1中国工业和信息化部网站备案查询
广播台